Evidence map›Paper›PMID 31390367›Full record

ArticlePloS one2019

Identification of lysine methylation in the core GTPase domain by GoMADScan.

Hirofumi Yoshino, Guowei Yin, Risa Kawaguchi, Konstantin I Popov, Brenda Temple, Mika Sasaki, Satoshi Kofuji, Kara Wolfe, Kaori Kofuji, Koichi Okumura and 11 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Biomarker Landscape in RASopathies.International journal of molecular sciences · 2024
    Review
  2. Molecular Mechanisms of Medicinal PlantCurrent pharmaceutical design · 2024
    Article
  3. Article
  4. Review
  5. Post-translational modification of RAS proteins.Current opinion in structural biology · 2021
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 2 countries.

Hirofumi YoshinoDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Guowei YinDepartment of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.ORCID 0000-0003-2669-7160
Risa KawaguchiDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Konstantin I PopovDepartment of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Brenda TempleUniversity of North Carolina, R. L. Juliano Structural Bioinformatics Core Facility, Chapel Hill, North Carolina, United States of America.
Mika SasakiDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Satoshi KofujiDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Kara WolfeDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Kaori KofujiDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Koichi OkumuraDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Jaskirat RandhawaDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Akshiv MalhotraDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Nazanin MajdDepartment of Neurology, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Yoshiki IkedaDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Hiroko ShimadaDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Emily Rose KahoudHarvard Medical School, Department of Medicine and Beth Israel Deaconess Medical Center, Division of Signal Transduction, Boston, Massachusetts, United States of America.
Sasson HavivHarvard Medical School, Department of Medicine and Beth Israel Deaconess Medical Center, Division of Signal Transduction, Boston, Massachusetts, United States of America.
Shigeki IwaseDepartment of Human Genetics, University of Michigan, 5815 Medical Science II, Ann Arbor, Michigan, United States of America.
John M AsaraHarvard Medical School, Department of Medicine and Beth Israel Deaconess Medical Center, Division of Signal Transduction, Boston, Massachusetts, United States of America.
Sharon L CampbellDepartment of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Atsuo T SasakiDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.ORCID 0000-0003-2963-4501
University of Cincinnati Medical Center · USUniversity of North Carolina at Chapel Hill · USBeth Israel Deaconess Medical Center · USAllen Institute for Brain Science · USThe University of Tokyo · JPUniversity of Michigan · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Tuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9M
Project 4: The role of codon bias in RAS tumorigenesisP01CA203657 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUNTER, CHRISTOPHER M · 2016 to 2020
$7.9M
Structure and Mechanism of G-proteins and cell adhesion proteins in regulation of cell growth and motilityR35GM134962 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sharon L Campbell · 2020 to 2026
$4.2M
Targeting the Novel PI5P4K Pathway to Induce Glioblastoma SenescenceR01NS089815 · NINDS · UNIVERSITY OF CINCINNATI · PI SASAKI, ATSUO · 2014 to 2018
$1.7M
Regulation of Ras by MonoubiquitinationR01GM106227 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAMPBELL, SHARON L · 2013 to 2016
$1.5M
Synthetic Lethal Combination of KRP203/Fingolimod with PI3K signaling for glioblastoma multiforme death by catastrophic vacuolizationR21NS100077 · NINDS · UNIVERSITY OF CINCINNATI · PI SASAKI, ATSUO · 2016 to 2017
$448k
NCI NIH HHS P01 CA120964NCI NIH HHS P01 CA203657NCI NIH HHS P30 CA016086NIGMS NIH HHS R01 GM106227NIGMS NIH HHS R35 GM134962NINDS NIH HHS R01 NS089815NINDS NIH HHS R21 NS100077
6 · The paper itself

Abstract

RAS is the founding member of a superfamily of GTPases and regulates signaling pathways involved in cellular growth control. While recent studies have shown that the activation state of RAS can be controlled by lysine ubiquitylation and acetylation, the existence of lysine methylation of the RAS superfamily GTPases remains unexplored. In contrast to acetylation, methylation does not alter the side chain charge and it has been challenging to deduce its impact on protein structure by conventional amino acid substitutions. Herein, we investigate lysine methylation on RAS and RAS-related GTPases. We developed GoMADScan (Go language-based Modification Associated Database Scanner), a new user-friendly application that scans and extracts posttranslationally modified peptides from databases. The GoMADScan search on PhosphoSitePlus databases identified methylation of conserved lysine residues in the core GTPase domain of RAS superfamily GTPases, including residues corresponding to RAS Lys-5, Lys-16, and Lys-117. To follow up on these observations, we immunoprecipitated endogenous RAS from HEK293T cells, conducted mass spectrometric analysis and found that RAS residues, Lys-5 and Lys-147, undergo dimethylation and monomethylation, respectively. Since mutations of Lys-5 have been found in cancers and RASopathies, we set up molecular dynamics (MD) simulations to assess the putative impact of Lys-5 dimethylation on RAS structure. Results from our MD analyses predict that dimethylation of Lys-5 does not significantly alter RAS conformation, suggesting that Lys-5 methylation may alter existing protein interactions or create a docking site to foster new interactions. Taken together, our findings uncover the existence of lysine methylation as a novel posttranslational modification associated with RAS and the RAS superfamily GTPases, and putative impact of Lys-5 dimethylation on RAS structure.

Indexed as

Protein Processing, Post-TranslationalAmino Acid SequenceData MiningGTP PhosphohydrolasesLysineMethylationMolecular Dynamics SimulationProtein DomainsGTP PhosphohydrolasesLysine

Identifiers

PMID31390367
PMCPMC6685615
OpenAlexW2965826856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.